I agree that this site is using cookies. You can find further informations here.
X
Al‐Kali, Aref
303  results:
Search for persons X
?
1

Cardiac events in newly diagnosed acute myeloid leukaemia d..:

Johnson, Isla M. ; Karrar, Omer ; Rana, Masooma...
British Journal of Haematology.  204 (2024)  4 - p. 1232-1237 , 2024
Link: https://doi.org/10.1111/..
 
?
2

The clinical and molecular spectrum of ETV6 mutated myeloid..:

Gurney, Mark ; Chekkaf, Ismahene ; Baranwal, Anmol...
British Journal of Haematology.  202 (2023)  2 - p. 279-283 , 2023
Link: https://doi.org/10.1111/..
 
?
3

TP53 variant allele frequency and therapy‐related setting i..:

Tefferi, Ayalew ; Fleti, Farah ; Chan, Onyee...
British Journal of Haematology.  204 (2023)  4 - p. 1243-1248 , 2023
Link: https://doi.org/10.1111/..
 
?
4

TP53 mutations and variant allele frequency in myelodysplas..:

Fleti, Farah ; Chan, Onyee ; Singh, Amritpal...
American Journal of Hematology.  98 (2023)  4 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
5

Phase 1/1b study of azacitidine and hedgehog pathway inhibi..:

Tibes, Raoul ; Kosiorek, Heidi E. ; Dueck, Amylou C....
Cancer.  129 (2023)  15 - p. 2321-2330 , 2023
Link: https://doi.org/10.1002/..
 
?
6

A phase II study of combination daunorubicin, cytarabine (A..:

Al‐Kali, Aref ; Tibes, Raoul ; Atherton, Pamela...
American Journal of Hematology.  98 (2023)  3 - p. 472-480 , 2023
Link: https://doi.org/10.1002/..
 
?
7

Spectrum of renal pathological findings in patients with ch..:

Gipe, Nate ; Leung, Nelson ; Lasho, Terra...
American Journal of Hematology.  98 (2023)  6 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
8

A phase 2 and pharmacological study of sapanisertib in pati..:

Al‐Kali, Aref ; Aldoss, Ibrahim ; Atherton, Pamela J....
Cancer Medicine.  12 (2023)  23 - p. 21229-21239 , 2023
Link: https://doi.org/10.1002/..
 
?
9

Sodium‐glucose co‐transporter‐2 inhibitor use and JAK2 unmu..:

Gangat, Naseema ; Abdallah, Mostafa ; Szuber, Natasha...
American Journal of Hematology.  98 (2023)  7 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
10

Venetoclax and hypomethylating agent combination therapy in..:

Gangat, Naseema ; Karrar, Omer ; Iftikhar, Moazah...
American Journal of Hematology.  99 (2023)  2 - p. 193-202 , 2023
Link: https://doi.org/10.1002/..
 
?
11

Mast cell cytomorphology and treatment outcome in mast cell..:

Tefferi, Ayalew ; Pardanani, Animesh ; Al‐Kali, Aref...
American Journal of Hematology.  99 (2023)  1 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
12

Reappraisal of mast cell leukemia based on a single institu..:

Pardanani, Animesh ; Tefferi, Ayalew ; Al‐Kali, Aref...
American Journal of Hematology.  99 (2023)  1 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
13

Granularity in disease classification impacts survival pred..:

Tefferi, Ayalew ; Abdelmagid, Maymona ; Al‐Kali, Aref...
American Journal of Hematology.  99 (2023)  1 - p. 21-27 , 2023
Link: https://doi.org/10.1002/..
 
?
14

Venetoclax duration (14 vs. 21 vs. 28 days) in combination ..:

Karrar, Omer ; Abdelmagid, Maymona ; Rana, Masooma...
American Journal of Hematology.  99 (2023)  2 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
15

Venetoclax plus hypomethylating agents in DDX41‐mutated acu..:

Nanaa, Ahmad ; He, Rong ; Foran, James M....
British Journal of Haematology.  204 (2023)  1 - p. 171-176 , 2023
Link: https://doi.org/10.1111/..
 
1-15